Table 2 Relationship between TUSC3 expression and clinicopathological features of 125 patients with HCC
From: Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis
TUSC3 expression | |||||
|---|---|---|---|---|---|
Features | n | Negative | Positive | χ2 | P value |
Age (years) | |||||
 ≤ 50 | 49 | 36 (73.5%) | 13 (26.5%) | 1.805 | 0.179 |
 > 50 | 76 | 47 (61.8%) | 29 (38.2%) | ||
Gender | |||||
 Male | 109 | 71 (65.1%) | 38 (34.9%) | 0.608 | 0.435 |
 Female | 16 | 12 (75.0%) | 4 (25.0%) | ||
Tumor size (diameters) (cm) | |||||
 ≤ 5 | 64 | 34 (53.1%) | 30 (46.9%) | 10.359 | 0.001 |
 > 5 | 61 | 49 (80.3%) | 12 (19.7%) | ||
Number of tumors | |||||
 = 1 | 93 | 59 (63.4%) | 34 (36.6%) | 1.426 | 0.232 |
 > 1 | 32 | 24 (75.0%) | 8 (25.0%) | ||
Differentiation | |||||
 Poor | 35 | 28 (80.0%) | 7 (20.0%) |  |  |
 Moderate | 75 | 50 (66.7%) | 25 (33.3%) | 10.255 | 0.006 |
 High | 15 | 5 (33.3%) | 10 (66.7%) |  |  |
Vascular invasion | |||||
 Absent | 60 | 39 (65.0%) | 21 (35.0%) | 1.101 | 0.750 |
 Present | 65 | 44 (67.7%) | 21 (32.3%) | ||
Tumor capsule | |||||
 Missing | 20 | 13 (65.0%) | 7 (35.0%) | 0.021 | 0.885 |
 Complete | 105 | 70 (66.7%) | 35(33.3%) | ||
AFP (ug/l) | |||||
 ≤ 20 | 51 | 31 (60.8%) | 20 (39.2%) | 1.218 | 0.270 |
 > 20 | 74 | 52(70.3%) | 22 (29.7%) | ||
HBsAg | |||||
 Negative | 22 | 15 (68.2%) | 7 (31.8%) | 0.038 | 0.845 |
 Positive | 103 | 68 (66.0%) | 35 (34.0%) | ||
Child–Pugh grade | |||||
 A | 101 | 64 (63.4%) | 37 (36.6%) | 2.170 | 0.141 |
 B | 24 | 19 (79.2%) | 5 (20.8%) | ||
BCLC stage | |||||
 A–B | 30 | 15 (50.0%) | 15 (50.0%) | 4.759 | 0.029 |
 C–D | 95 | 68 (66.4%) | 27(33.6%) | ||